Expert Opinion on Drug Metabolism & Toxicology

Papers
(The H4-Index of Expert Opinion on Drug Metabolism & Toxicology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer87
Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity74
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion55
High-throughput PBTK models for in vitro to in vivo extrapolation49
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?46
Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols?44
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study44
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity40
The pharmacokinetics of antibiotics in cystic fibrosis40
Alterations in drug disposition in older adults: a focus on geriatric syndromes39
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting38
Drug metabolism in the lungs: opportunities for optimising inhaled medicines35
Tumor grafted – chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation34
Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems33
Multi-organ-on-a-chip for pharmacokinetics and toxicokinetic study of drugs29
SULT genetic polymorphisms: physiological, pharmacological and clinical implications27
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization27
Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder26
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?26
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes25
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies25
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review24
Genetic risk factors in the development of idiosyncratic drug-induced liver injury22
0.16052985191345